The Division for Cancer Pharmacology (DCP) serves members with interests
in all aspects of basic and translational cancer pharmacology research.
Specific areas include, (but are not limited to) discovery and
preclinical development of new anticancer agents, preclinical toxicology
and adverse reactions to
anticancer drugs, technical developments in novel cancer-related target
and therapeutic identification, mechanisms of anticancer drug
resistance, mechanistic studies of novel therapeutic regimens,
pharmacogenetics of anticancer therapeutics, and biomarker studies in
anticancer drug response.
- To increase outreach efforts with the goal of increasing membership
from both academia and industry and their participation in ASPET
- To develop networking strategies for the benefit of junior and senior investigators
- To increasing participation of industry-associated members in development of symposia for EB
- To develop programming ideas including workshops addressing current
challenges in cancer pharmacology (e.g. reproducibility and relevance of
animal models of cancer)
Posting on social media about the DCP division? Use #ASPETDCP.
Last Updated: June 6, 2019